Literature DB >> 22100141

Anthelmintic resistance in equine parasites - detection, potential clinical relevance and implications for control.

Georg von Samson-Himmelstjerna1.   

Abstract

During the past two decades anthelmintic resistance in equine parasites has been found in the group of small strongyle species (cyathostomins) and in the ascarid species Parascaris equorum. The ubiquitous nature and possible severe consequences of disease with these nematodes make them the prime targets of current worm control programmes. Traditional control strategies mainly rely on the strategic application of anthelmintics, currently represented by three major drug classes: benzimidazoles (BZ), the tetrahydropyrimidine pyrantel (PYR) and macrocyclic lactones (ML). Following decades of routine and frequent anthelmintic applications, many cyathostomin populations on horse farms in industrialised countries must be considered as resistant to BZ anthelmintics. However, to date no published cases of cyathostomin disease specifically associated with anthelmintic resistance were reported. Possibly this is due to the generally subclinical and unspecific symptoms associated with cyathostomin infections. Nevertheless, exclusive reliance on the ML drug class may increase the threat of clinical disease due to drug-resistant cyathostomins. More recently, P. equorum has been reported as having developed resistance against ivermectin and moxidectin, two representatives of the ML-class. These anthelmintics are currently the most frequently used drug class in horses. This nematode species is mainly found in foals and in younger horses due to the development of immunity following exposure to infection. Infection with P. equorum can result in clinically drastic consequences such as obstruction and/or penetration of the small intestine, the latter usually leading to death. In conclusion, on horse farms the efficacy of anthelmintic treatments should be examined routinely for each drug class. Several factors can influence the rate at which anthelmintic resistance develops; high frequency of treatment being one of the most important. Modern control strategies should therefore attempt to significantly reduce anthelmintic treatments. Several pasture and farm management practices found to be negatively associated with nematode and anthelmintic resistance prevalence will be discussed in the review presented here.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22100141     DOI: 10.1016/j.vetpar.2011.10.010

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  29 in total

1.  Absence of Polymorphisms in Codons 167, 198 and 200 of All Seven β-Tubulin Isotypes of Benzimidazole Susceptible and Resistant Parascaris spp. Specimens from Australia.

Authors:  Murat Özben; Georg von Samson-Himmelstjerna; Malene K B Freiin von Streit; Edwina J A Wilkes; Kristopher J Hughes; Jürgen Krücken
Journal:  Pathogens       Date:  2022-04-20

2.  Occurrence of Strongylid Nematode Parasites on Horse Farms in Berlin and Brandenburg, Germany, With High Seroprevalence of Strongylus vulgaris Infection.

Authors:  Laura Jürgenschellert; Jürgen Krücken; Eric Bousquet; Jürgen Bartz; Nina Heyer; Martin K Nielsen; Georg von Samson-Himmelstjerna
Journal:  Front Vet Sci       Date:  2022-06-10

3.  Fecundity of various species of strongylids (Nematoda: Strongylidae)--parasites of domestic horses.

Authors:  T A Kuzmina; E T Lyons; S C Tolliver; I I Dzeverin; V A Kharchenko
Journal:  Parasitol Res       Date:  2012-08-19       Impact factor: 2.289

4.  Efficacy of selected anthelmintic drugs against cyathostomins in horses in the federal state of Brandenburg, Germany.

Authors:  Juliane K Fischer; Barbara Hinney; Matthew J Denwood; Donato Traversa; Georg von Samson-Himmelstjerna; Peter-Henning Clausen
Journal:  Parasitol Res       Date:  2015-09-04       Impact factor: 2.289

5.  Transgenically expressed Parascaris P-glycoprotein-11 can modulate ivermectin susceptibility in Caenorhabditis elegans.

Authors:  I Jana I Janssen; Jürgen Krücken; Janina Demeler; Georg von Samson-Himmelstjerna
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2015-04-08       Impact factor: 4.077

6.  A survey on parasite management by equine veterinarians highlights the need for a regulation change.

Authors:  Guillaume Sallé; Jacques Cabaret
Journal:  Vet Rec Open       Date:  2015-09-14

Review 7.  Recent advances in candidate-gene and whole-genome approaches to the discovery of anthelmintic resistance markers and the description of drug/receptor interactions.

Authors:  Andrew C Kotze; Peter W Hunt; Philip Skuce; Georg von Samson-Himmelstjerna; Richard J Martin; Heinz Sager; Jürgen Krücken; Jane Hodgkinson; Anne Lespine; Aaron R Jex; John S Gilleard; Robin N Beech; Adrian J Wolstenholme; Janina Demeler; Alan P Robertson; Claude L Charvet; Cedric Neveu; Ronald Kaminsky; Lucien Rufener; Melanie Alberich; Cecile Menez; Roger K Prichard
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2014-08-13       Impact factor: 4.077

8.  Utilization of computer processed high definition video imaging for measuring motility of microscopic nematode stages on a quantitative scale: "The Worminator".

Authors:  Bob Storey; Chris Marcellino; Melissa Miller; Mary Maclean; Eman Mostafa; Sue Howell; Judy Sakanari; Adrian Wolstenholme; Ray Kaplan
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2014-08-28       Impact factor: 4.077

9.  Action of Carvacrol on Parascaris sp. and Antagonistic Effect on Nicotinic Acetylcholine Receptors.

Authors:  Sasa M Trailovic; Milan Rajkovic; Djordje S Marjanovic; Cédric Neveu; Claude L Charvet
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-26

10.  The effectiveness of faecal removal methods of pasture management to control the cyathostomin burden of donkeys.

Authors:  Christopher J Corbett; Sandy Love; Anna Moore; Faith A Burden; Jacqui B Matthews; Matthew J Denwood
Journal:  Parasit Vectors       Date:  2014-01-24       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.